HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study

• Published in: Journal of the International AIDS Society Vol. 27; no. 5; pp. e26252 - n/a
• Main Authors: Psaros, Christina, Goodman, Georgia R., Lee, Jasper S., Rice, Whitney, Kelley, Colleen F., Oyedele, Temitope, Coelho, Lara E., Phanuphak, Nittaya, Singh, Yashna, Middelkoop, Keren, Griffith, Sam, McCauley, Marybeth, Rooney, James, Rinehart, Alex R., Clark, Jesse, Go, Vivian, Sugarman, Jeremy, Fields, Sheldon D., Adeyeye, Adeola, Grinsztejn, Beatriz, Landovitz, Raphael J., Safren, Steven A.
• Format: Journal Article
• Language: English
• Published: Switzerland John Wiley & Sons, Inc 01.05.2024; Wiley
• Subjects: Adult; Analysis; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - therapeutic use; Biological products industry; Brazil; Cisgender; Demographics; Diketopiperazines; Disease prevention; Education; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use; Ethnicity; Female; Gender identity; Hispanic Americans; HIV; HIV Infections - drug therapy; HIV Infections - prevention & control; HIV prevention; Homosexuality, Male; Human immunodeficiency virus; Humans; injectable PrEP; Injection; Injections; Interviews; Interviews as Topic; Male; Marital status; Medication Adherence - statistics & numerical data; men who have sex with men; Middle Aged; Pre-Exposure Prophylaxis - methods; Prevention; pre‐exposure prophylaxis; Prophylaxis; Pyridines - administration & dosage; Pyridines - therapeutic use; Pyridones - administration & dosage; Pyridones - therapeutic use; qualitative; Sexually transmitted diseases; Sociodemographics; STD; Tenofovir - administration & dosage; Tenofovir - therapeutic use; Transgender people; Transgender persons; Transgender Persons - psychology; transgender women; Young Adult; Brazil; South Africa; United States; Illinois; Atlanta Georgia; Rio de Janeiro Brazil; Chicago Illinois; United States > US; pre‐exposure prophylaxis; HIV prevention; qualitative; injectable PrEP; men who have sex with men; transgender women
• ISSN: 1758-2652; 1758-2652
• DOI: 10.1002/jia2.26252

Introduction HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre‐exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial. Methods Participants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non‐adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis. Results Participants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study‐related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non‐judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection‐related anxiety, which abated with time and when given some measure of control (e.g. pre‐injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules). Conclusions Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non‐judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective.